- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07641764
3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy (3DP-DPN)
14. juni 2026 oppdatert av: Anbreena Rasool, University of Faisalabad
Comparative Effect of 3D Printed Customized Insoles and Ready to Wear Insoles on Plantar Pressure Changes in Patients With Diabetic Neuropathy
Diabetic neuropathy is a condition caused by chronic high blood glucose levels that damage nerves over time, frequently causing abnormal plantar pressure and increasing the risk of foot ulcers and impaired mobility.
Insoles are widely used to redistribute pressure and improve comfort.
This study compares the effect of 3D printed customized insoles versus ready-to-wear insoles on plantar pressure changes in patients with diabetic neuropathy.
The study is a randomized controlled trial with 22 participants randomly allocated to two groups: one receiving 3D printed customized insoles and the other receiving ready-to-wear insoles.
Plantar pressure is measured using piezoresistive sensors and an Arduino Nano Unit.
Secondary outcomes include foot health status (FSHQ questionnaire), satisfaction with assistive technology (QUEST 2.0), and neuropathy severity (NSS and NDS questionnaires).
Assessments occur at baseline, 4 weeks, and 8 weeks.
Studieoversikt
Status
Aktiv, ikke rekrutterende
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a single-blind, parallel-group randomized controlled trial conducted at DHQ-1 and DHQ-2 hospitals in Okara, Pakistan.
Participants are adults aged 35-65 years with diagnosed diabetic neuropathy who can walk independently without aids.
Exclusion criteria include foot ulcers, external wounds, recent surgery, major limb amputation, foot drop, peripheral vascular disease, neuromuscular diseases, and Charcot arthropathy.
A consecutive sampling technique is used to recruit 22 participants.
Randomization is performed using a computer-generated sequence.
Participants are blinded to their group allocation.
Group A receives 3D printed customized insoles tailored to individual foot morphology using 3D scanning and printing technology.
These insoles provide arch support and gait alignment.
Group B receives ready-to-wear insoles providing general cushioning and basic support.
Both groups follow an 8-week intervention protocol: participants wear insoles for a minimum of 6 hours per day, 5 days per week, and perform level walking on a 28-meter pathway at self-selected speed.
The protocol is divided into phases: weeks 1-2 for acclimatization and footwear assessment using Semmes-Weinstein 10g monofilament; weeks 3-4 for pressure adaptation and skin monitoring; weeks 5-6 for enhanced foot function and balance improvement; weeks 7-8 for final assessment.
Primary outcome: plantar pressure measured via piezoresistive sensors and Arduino Nano Unit.
Secondary outcomes: Foot Health Status Questionnaire (FSHQ), Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0), Neuropathy Symptom Score (NSS), and Neuropathy Deficit Score (NDS).
Data are collected at baseline, week 4, and week 8. Statistical analysis uses SPSS version 22.
Studietype
Intervensjonell
Registrering (Antatt)
22
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Punjab Province
-
Faisalābad, Punjab Province, Pakistan, 3800
- The University of Faisalabad
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Age 35 to 65 years
- Diagnosed with diabetes mellitus
- Clinical diagnosis of diabetic peripheral neuropathy
- Ability to walk independently without walking aids
- Normal cognitive function
- Corrected or uncorrected vision sufficient for safe ambulation
- Willingness to provide written informed consent
Exclusion Criteria:
- Presence of active foot ulcer
- External wound on lower extremity
- History of lower limb surgery within past 6 months
- Major lower limb amputation
- Foot drop
- Peripheral vascular disease
- Neuromuscular diseases (e.g., stroke, Parkinson's disease, multiple sclerosis)
- Charcot arthropathy
- Inability to comply with study protocol
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Group A: 3D Printed Customized Insoles
Participants in this group receive 3D printed customized insoles tailored to individual foot morphology.
Insoles are designed to provide arch support and gait alignment.
Participants wear insoles for minimum 6 hours/day, 5 days/week for 8 weeks, following a phased protocol of acclimatization, pressure adaptation, and function improvement.
|
3D printed customized insoles are fabricated using 3D scanning of the participant's foot to capture individual morphology.
The insoles are printed using thermoplastic polyurethane (TPU) or similar 3D printing filament.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
Ready-to-wear insoles are prefabricated insoles providing general cushioning and shock absorption.
These insoles are not customized to individual foot morphology.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
|
|
Aktiv komparator: Group B: Ready-to-Wear Insoles
Participants in this group receive prefabricated ready-to-wear insoles providing general cushioning and basic support.
Participants wear insoles for minimum 6 hours/day, 5 days/week for 8 weeks, following the same phased protocol as the experimental group.
|
Ready-to-wear insoles are prefabricated insoles providing general cushioning and shock absorption.
These insoles are not customized to individual foot morphology.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Plantar Pressure Distribution
Tidsramme: Baseline (Week 0), Mid-intervention (Week 4), Post-intervention (Week 8)
|
Plantar pressure is measured using piezoresistive sensors connected to an Arduino Nano Unit.
Participants walk barefoot across the sensor platform.
The sensor records pressure distribution across the plantar surface in kilopascals (kPa).
Higher pressure values indicate greater plantar load, which is associated with increased risk of foot ulceration.
Lower pressure values indicate better offloading.
|
Baseline (Week 0), Mid-intervention (Week 4), Post-intervention (Week 8)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Foot Health Status Questionnaire (FSHQ) Score
Tidsramme: Baseline (Week 0), Week 4, Week 8
|
The Foot Health Status Questionnaire (FSHQ) is a validated instrument assessing foot-related quality of life.
It includes domains of foot pain, foot function, footwear, and general foot health.
Each item is scored on a Likert scale.
Minimum score is zero and maximum score is 100.
scores are generally classified into ranges such as Very Low: 0-24.9
Low:25-49.9
Medium: 50-74.9
High: 75-100 HIgher score indicates better foot health and lower score indicates worst foot health.
|
Baseline (Week 0), Week 4, Week 8
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. januar 2026
Primær fullføring (Antatt)
30. juni 2026
Studiet fullført (Antatt)
15. juli 2026
Datoer for studieregistrering
Først innsendt
6. juni 2026
Først innsendt som oppfylte QC-kriteriene
6. juni 2026
Først lagt ut (Faktiske)
11. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
17. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
14. juni 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Sykdommer i nervesystemet
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Nevromuskulære sykdommer
- Sykdommer i det perifere nervesystemet
- Sukkersyke
- Diabetiske angiopatier
- Diabetes komplikasjoner
- Hudsykdommer
- Hudsår
- Bensår
- Fotsår
- Hud- og bindevevssykdommer
- Diabetiske nevropatier
- Diabetisk fot
Andre studie-ID-numre
- TUF/EIRB/ 195 /26
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .